BMY•benzinga•
Reported Earlier, Philochem Licenses Global Rights To Prostate Cancer Radiopharmaceutical OncoACP3 To RayzeBio, A Bristol-Myers Squibb Company, In Deal Worth Up To $1.35B
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 11, 2025 by benzinga